report earn result review recent
corpor progress reiter market outperform rate increas
price target base dcf sotp valuat
methodolog follow updat financi model
concert report net loss per share vs
estim loss per share revenu
larg non-cash consider receiv part compani licens
agreement pcsa nc
total oper expens quarter line
estim gener administr expens
versu estim expens versu
estim
equival quarter-end total compani
expect suffici fund oper
call manag highlight continu expect top-lin data
cohort phase iia clinic trial alopecia
areata remind investor believ read-out repres
next signific value-driv catalyst share regard rehear
decis deni inter part review ipr patent recent
grant mo pt bayko patent trial appeal board
ptab oral argument continu expect decemb
concert continu anticip initi phase single-ascending-dos studi
healthi volunt deuter form d-serin potenti
treatment schizophrenia
updat financi model assign bulk pipelin valuat
compani lead asset deuter form ruxolitinib jakafi
note estim peak sale set alopecia areata
figur highlight chang model well
summari valuat methodolog although highli promis asset
opinion remain potenti upsid estim pend safeti
data human
continu see signific upsid potenti pioneer deuter
drug compani remain posit share see
opportun growth next sever year includ
opinion compani dce platform spearhead
requisit compon allow becom one
lead develop uniqu deuterated-therapeut compound
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
abridg incom statement mm jmp estimateactualvari jmp vs actual licens profit- oper develop incom incom dilut basic share share result inc
figur chang model
figur synthesi valuat approach
fy mm oldnewoldnewoldnewoldnewoldnewlicens profit- oper research develop gener oper incom incom pre-tax net basic dilut basic share share valuat approachesapproachvaluationweightdcf inc
npv equiv total discount rateconcert pharmaceut discount revenu us sales- ex-u revenues- royalti rate total revenu product oper incom tax oper valu cash debt dilut share outstand growth concert pharmaceut inc
total npv discount rate discount phase singl ascend dose studi healthi volunt data phase iia alopecia phase iib trial alopecia readout phase trial alzheim decis ipr challeng us patent figur incom statement
statement product sale research develop good expens research oper incom loss incom expens invest expensepay gsktotal incom net incom tax benefit incom redeem convert prefer stockconsolid net incom ep common dilut ep common basic share share chang dilut share outstand inc inc
clinical-stag biopharmaceut compani seek discov develop novel small molecul drug
improv exist drug clinic candid via deuterium substitut deuterium substitut lead drug superior
pharmacokinet metabol properti improv clinic safeti toler and/or efficaci deuter analog approv drug may also
abl benefit expedit pathway fda approv firm current number clinical-stag product candid includ
alopecia areata neurolog psychiatr disord collabor
firm also collabor deuter compound includ activ ingredi xyrem
clinic develop narcolepsi lastli compani recent nomin novel develop candid potenti treatment
neg symptom associ schizophrenia known deuter form d-serin
clinic risk product undergo clinic trial may seriou safeti concern lack efficaci fail demonstr statist signific
would preclud continu clinic develop eventu commerci compani deuter chemic
entiti dce platform technolog proven like downsid share price risk viabil compani
addit yet demonstr abil success conduct large-scal pivot clinic trial obtain market approv
manufactur commerci scale product conduct sale market activ necessari success product commerci
collabor risk depend upon collabor third parti develop commerci
compani product candid expect continu futur cnce busi model reli make use dce platform
partner compani improv exist drug candid cnce prospect respect
product candid depend signific part upon success collabor
manufactur risk clinical-stag biopharmaceut compani appli extens knowledg deuterium chemistri discov
develop novel small molecul drug limit sourc deuterium collabor expos number
risk uncertainti associ compani deuterium suppli particular manufactur process mani compani
drug candid project requir larg quantiti deuterium late-stag clinic trial commerci consequ
advers impact cnce abil obtain deuterium oxid could signific impact compani abil develop
commerci product candid similarli cnce collabor also need obtain suppli deuterium subject risk
requir connect sourc deuterium similar one compani face
financi risk current deriv revenu research develop fund licens collabor
agreement compani yet profit histori oper loss expect continu near futur develop
pharmaceut product includ conduct preclin studi clinic trial time-consum expens uncertain process
take year complet must continu financ clinic trial complet may unabl secur addit
fund forc delay reduc elimin product develop program commerci effort compani incur
signific loss sinc incept expect loss occur next sever year
regulatori risk collabor may instanc abl secur clearanc fda compar foreign
regulatori author use expedit develop pathway unabl obtain clearanc collabor may
requir conduct addit preclin studi clinic trial beyond contempl could increas expens obtain
delay receipt necessari market approv
